CORRESP Filing
Acurx Pharmaceuticals, Inc.
Date: Jan. 2, 2026 · CIK: 0001736243 · Accession: 0001104659-26-000202
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-288595
Letter
Acurx Pharmaceuticals, Inc.
259 Liberty Avenue
Staten Island, NY 10305
January 2, 2026
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Alan Campbell
Re: Acurx Pharmaceuticals, Inc.
Registration Statement on Form S-3, as amended
Filed July 9, 2025
File No. 333-288595 (the "Registration Statement")
Acceleration Request
Ladies and Gentlemen:
In accordance with Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, Acurx Pharmaceuticals, Inc. (the "Registrant") hereby respectfully requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement to January 6, 2026, at 4:00 p.m., Eastern Time, or as soon as thereafter practicable.
The cooperation of the staff in meeting the timetable described above is very much appreciated.
Please contact Jeffrey D. Cohan of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Registrant, at (212) 692-6710 with any questions regarding this request.
Very truly yours,
Acurx Pharmaceuticals, Inc.
Show Raw Text
CORRESP 1 filename1.htm Acurx Pharmaceuticals, Inc. 259 Liberty Avenue Staten Island, NY 10305 January 2, 2026 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Alan Campbell Re: Acurx Pharmaceuticals, Inc. Registration Statement on Form S-3, as amended Filed July 9, 2025 File No. 333-288595 (the "Registration Statement") Acceleration Request Ladies and Gentlemen: In accordance with Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, Acurx Pharmaceuticals, Inc. (the "Registrant") hereby respectfully requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement to January 6, 2026, at 4:00 p.m., Eastern Time, or as soon as thereafter practicable. The cooperation of the staff in meeting the timetable described above is very much appreciated. Please contact Jeffrey D. Cohan of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Registrant, at (212) 692-6710 with any questions regarding this request. Very truly yours, Acurx Pharmaceuticals, Inc. /s/ David P. Luci David P. Luci President and Chief Executive Officer cc: Mintz, Levin. Cohn. Ferris. Glovsky and Popeo. P.C Ivan K. Blumenthal, Esq. Jeffrey D. Cohan, Esq.